STAMP2 increases oxidative stress and is critical for prostate cancer

EMBO Molecular Medicine

Volumn 7, Issue 3, 2015, Pages 315-331

  Jin, Yang ^a,b   Wang, Ling ^a   Qu, Su ^a   Sheng, Xia ^a,b   Kristian, Alexandr ^b   Mælandsmo, Gunhild M ^b   Pällmann, Nora ^a   Yuca, Erkan ^c   Tekedereli, Ibrahim ^c   Gorgulu, Kivanc ^c   Alpay, Neslihan ^c   Sood, Anil ^c   Lopez Berestein, Gabriel ^c   Fazli, Ladan ^d   Rennie, Paul ^d   Risberg, Bjørn ^b   Wæhre, Håkon ^a,b   Danielsen, Håvard E ^a,b   Ozpolat, Bulent ^c   Saatcioglu, Fahri ^a,b  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d VANCOUVER PROSTATE CENTRE   (Canada)

Author keywords

Activating transcription factor 4; Iron reductase; Prostate cancer; Reactive oxygen species; Six transmembrane protein of prostate 2

Indexed keywords

ACTIVATING TRANSCRIPTION FACTOR 4; PEPTIDES AND PROTEINS; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; ATF4 PROTEIN, HUMAN; FERRIC CITRATE IRON REDUCTASE; FLAVINE MONONUCLEOTIDE REDUCTASE; MEMBRANE PROTEIN; OXIDOREDUCTASE; STEAP4 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL; CANCER GRADING; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN EXPRESSION; TREATMENT RESPONSE; TUMOR GROWTH; UPREGULATION; ANIMAL; DISEASE MODEL; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE; XENOGRAFT;

ACTIVATING TRANSCRIPTION FACTOR 4; ANIMALS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FMN REDUCTASE; GENE EXPRESSION REGULATION; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MEMBRANE PROTEINS; MICE; OXIDATIVE STRESS; OXIDOREDUCTASES; PROSTATIC NEOPLASMS; REACTIVE OXYGEN SPECIES; TRANSPLANTATION, HETEROLOGOUS;

EID: 84929841991     PISSN: 17574676     EISSN: 17574684     Source Type: Journal    
DOI: 10.15252/emmm.201404181     Document Type: Article

References (49)

1. Arnold JT, Isaacs JT (2002) Mechanisms involved in the progression of androgen-independent prostate cancers: it is not only the cancer cell's fault. Endocr Relat Cancer 9: 61-73
2. Basu HS, Thompson TA, Church DR, Clower CC, Mehraein-Ghomi F, Amlong CA, Martin CT, Woster PM, Lindstrom MJ, Wilding G (2009) A small molecule polyamine oxidase inhibitor blocks androgen-induced oxidative stress and delays prostate cancer progression in the transgenic adenocarcinoma of the mouse prostate model. Cancer Res 69: 7689-7695
3. Bluemn EG, Nelson PS (2012) The androgen/androgen receptor axis in prostate cancer. Curr Opin Oncol 24: 251-257
4. Cafe C, Torri C, Bertorelli L, Tartara F, Tancioni F, Gaetani P, Rodriguez y Baena R, Marzatico F (1995) Oxidative events in neuronal and glial cell-enriched fractions of rat cerebral cortex. Free Radic Biol Med 19: 853-857
5. Chen X, Thakkar H, Tyan F, Gim S, Robinson H, Lee C, Pandey SK, Nwokorie C, Onwudiwe N, Srivastava RK (2001) Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer. Oncogene 20: 6073-6083
6. Cullinan SB, Diehl JA (2006) Coordination of ER and oxidative stress signaling: the PERK/Nrf2 signaling pathway. Int J Biochem Cell Biol 38: 317-332
7. Dayyani F, Gallick GE, Logothetis CJ, Corn PG (2011) Novel therapies for metastatic castrate-resistant prostate cancer. J Natl Cancer Inst 103: 1665-1675
8. ten Freyhaus H, Calay ES, Yalcin A, Vallerie SN, Yang L, Calay ZZ, Saatcioglu F, Hotamisligil GS (2012) Stamp2 controls macrophage inflammation through nicotinamide adenine dinucleotide phosphate homeostasis and protects against atherosclerosis. Cell Metab 16: 81-89
9. Frohlich DA, McCabe MT, Arnold RS, Day ML (2008) The role of Nrf2 in increased reactive oxygen species and DNA damage in prostate tumorigenesis. Oncogene 27: 4353-4362
10. Grasso CS, Wu YM, Robinson DR, Cao X, Dhanasekaran SM, Khan AP, Quist MJ, Jing X, Lonigro RJ, Brenner JC et al (2012) The mutational landscape of lethal castration-resistant prostate cancer. Nature 487: 239-243
11. Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, Sadri N, Yun C, Popko B, Paules R et al (2003) An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell 11: 619-633
12. Jin Y, Qu S, Tesikova M, Wang L, Kristian A, Maelandsmo GM, Kong H, Zhang T, Jeronimo C, Teixeira MR et al (2013) Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer. Proc Natl Acad Sci USA 110: E2572-E2581
13. Klokk TI, Kilander A, Xi Z, Waehre H, Risberg B, Danielsen HE, Saatcioglu F (2007) Kallikrein 4 is a proliferative factor that is overexpressed in prostate cancer. Cancer Res 67: 5221-5230
14. Knobel Y, Glei M, Osswald K, Pool-Zobel BL (2006) Ferric iron increases ROS formation, modulates cell growth and enhances genotoxic damage by 4-hydroxynonenal in human colon tumor cells. Toxicol In Vitro 20: 793-800
15. Korkmaz CG, Korkmaz KS, Kurys P, Elbi C, Wang L, Klokk TI, Hammarstrom C, Troen G, Svindland A, Hager GL et al (2005) Molecular cloning and characterization of STAMP2, an androgen-regulated six transmembrane protein that is overexpressed in prostate cancer. Oncogene 24: 4934-4945
16. Lai J, Lehman ML, Dinger ME, Hendy SC, Mercer TR, Seim I, Lawrence MG, Mattick JS, Clements JA, Nelson CC (2010) A variant of the KLK4 gene is expressed as a cis sense-antisense chimeric transcript in prostate cancer cells. RNA 16: 1156-1166
17. Landen CN Jr, Chavez-Reyes A, Bucana C, Schmandt R, Deavers MT, Lopez-Berestein G, Sood AK (2005) Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. Cancer Res 65: 6910-6918
18. Lewerenz J, Maher P (2011) Control of redox state and redox signaling by neural antioxidant systems. Antioxid Redox Signal 14: 1449-1465
19. Mehraein-Ghomi F, Basu HS, Church DR, Hoffmann FM, Wilding G (2010) Androgen receptor requires JunD as a coactivator to switch on an oxidative stress generation pathway in prostate cancer cells. Cancer Res 70: 4560-4568
20. Nelson WG, De Marzo AM, DeWeese TL, Isaacs WB (2004) The role of inflammation in the pathogenesis of prostate cancer. J Urol 172: S6-S11; discussion S11-12
21. Nick AM, Stone RL, Armaiz-Pena G, Ozpolat B, Tekedereli I, Graybill WS, Landen CN, Villares G, Vivas-Mejia P, Bottsford-Miller J et al (2011) Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst 103: 1596-1612
22. Ohgami RS, Campagna DR, Greer EL, Antiochos B, McDonald A, Chen J, Sharp JJ, Fujiwara Y, Barker JE, Fleming MD (2005) Identification of a ferrireductase required for efficient transferrin-dependent iron uptake in erythroid cells. Nat Genet 37: 1264-1269
23. Ohgami RS, Campagna DR, McDonald A, Fleming MD (2006) The Steap proteins are metalloreductases. Blood 108: 1388-1394
24. Okada S (1996) Iron-induced tissue damage and cancer: the role of reactive oxygen species-free radicals. Pathol Int 46: 311-332
25. Paschos A, Pandya R, Duivenvoorden WC, Pinthus JH (2013) Oxidative stress in prostate cancer: changing research concepts towards a novel paradigm for prevention and therapeutics. Prostate Cancer Prostatic Dis 16: 217-225
26. Prensner JR, Rubin MA, Wei JT, Chinnaiyan AM (2012) Beyond PSA: the next generation of prostate cancer biomarkers. Sci Transl Med 4: 127rv123
27. Riganti C, Gazzano E, Polimeni M, Costamagna C, Bosia A, Ghigo D (2004) Diphenyleneiodonium inhibits the cell redox metabolism and induces oxidative stress. J Biol Chem 279: 47726-47731
28. Ripple MO, Henry WF, Rago RP, Wilding G (1997) Prooxidant-antioxidant shift induced by androgen treatment of human prostate carcinoma cells. J Natl Cancer Inst 89: 40-48
29. Ros S, Santos CR, Moco S, Baenke F, Kelly G, Howell M, Zamboni N, Schulze A (2012) Functional metabolic screen identifies 6-phosphofructo-2-kinase/fructose-2, 6-biphosphatase 4 as an important regulator of prostate cancer cell survival. Cancer Discov 2: 328-343
30. Rzymski T, Milani M, Singleton DC, Harris AL (2009) Role of ATF4 in regulation of autophagy and resistance to drugs and hypoxia. Cell Cycle 8: 3838-3847
31. Serrander L, Cartier L, Bedard K, Banfi B, Lardy B, Plastre O, Sienkiewicz A, Forro L, Schlegel W, Krause KH (2007) NOX4 activity is determined by mRNA levels and reveals a unique pattern of ROS generation. Biochem J 406: 105-114
32. Shao L, Tekedereli I, Wang J, Yuca E, Tsang S, Sood A, Lopez-Berestein G, Ozpolat B, Ittmann M (2012) Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res 18: 6648-6657
33. Shen MM, Abate-Shen C (2010) Molecular genetics of prostate cancer: new prospects for old challenges. Genes Dev 24: 1967-2000
34. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62: 10-29
35. Sramkoski RM, Pretlow TG II, Giaconia JM, Pretlow TP, Schwartz S, Sy MS, Marengo SR, Rhim JS, Zhang D, Jacobberger JW (1999) A new human prostate carcinoma cell line, 22Rv1. In Vitro Cell Dev Biol Anim 35: 403-409
36. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, Rupairmoole R, Armaiz-Pena GN, Pecot CV, Coward J et al (2012) Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 366: 610-618
37. Sun XY, Donald SP, Phang JM (2001) Testosterone and prostate specific antigen stimulate generation of reactive oxygen species in prostate cancer cells. Carcinogenesis 22: 1775-1780
38. Tam NN, Gao Y, Leung YK, Ho SM (2003) Androgenic regulation of oxidative stress in the rat prostate: involvement of NAD(P)H oxidases and antioxidant defense machinery during prostatic involution and regrowth. Am J Pathol 163: 2513-2522
39. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B et al (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22
40. Velasco AM, Gillis KA, Li Y, Brown EL, Sadler TM, Achilleos M, Greenberger LM, Frost P, Bai W, Zhang Y (2004) Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology 145: 3913-3924
41. Wang L, Jin Y, Arnoldussen YJ, Jonson I, Qu S, Maelandsmo GM, Kristian A, Risberg B, Waehre H, Danielsen HE et al (2010) STAMP1 is both a proliferative and an antiapoptotic factor in prostate cancer. Cancer Res 70: 5818-5828
42. Wang Q, Tiffen J, Bailey CG, Lehman ML, Ritchie W, Fazli L, Metierre C, Feng YJ, Li E, Gleave M et al (2013) Targeting amino acid transport in metastatic castration-resistant prostate cancer: effects on cell cycle, cell growth, and tumor development. J Natl Cancer Inst 105: 1463-1473
43. Wellen KE, Fucho R, Gregor MF, Furuhashi M, Morgan C, Lindstad T, Vaillancourt E, Gorgun CZ, Saatcioglu F, Hotamisligil GS (2007) Coordinated regulation of nutrient and inflammatory responses by STAMP2 is essential for metabolic homeostasis. Cell 129: 537-548
44. Yap TA, Zivi A, Omlin A, de Bono JS (2011) The changing therapeutic landscape of castration-resistant prostate cancer. Nat Rev Clin Oncol 8: 597-610
45. Ye J, Koumenis C (2009) ATF4, an ER stress and hypoxia-inducible transcription factor and its potential role in hypoxia tolerance and tumorigenesis. Curr Mol Med 9: 411-416
46. Ye J, Kumanova M, Hart LS, Sloane K, Zhang H, De Panis DN, Bobrovnikova-Marjon E, Diehl JA, Ron D, Koumenis C (2010) The GCN2-ATF4 pathway is critical for tumour cell survival and proliferation in response to nutrient deprivation. EMBO J 29: 2082-2096
47. Ying W (2008) NAD+/NADH and NADP+/NADPH in cellular functions and cell death: regulation and biological consequences. Antioxid Redox Signal 10: 179-206
48. Yu R, Mandlekar S, Ruben S, Ni J, Kong ANT (2000) Tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in androgen-independent prostate cancer cells. Cancer Res 60: 2384-2389
49. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L, McDonald C, Thomas R, Dhir R, Finkelstein S et al (2004) Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 22: 2790-2799